Alivexis

Tokyo, Japan· Est. 2020

Alivexis develops novel small-molecule drugs for cancer and inflammatory diseases using its proprietary computational drug discovery platform.

alivexis.com

Is this your company? Claim your profile to update info and connect with investors.

Claim profile

Private Company

Funding information not available

AI Company Overview

Alivexis develops novel small-molecule drugs for cancer and inflammatory diseases using its proprietary computational drug discovery platform.

OncologyImmunology

Technology Platform

Proprietary ModBind™ simulation engine integrated with advanced structural analysis and supercomputing for rational design of small molecules against difficult biological targets.

Opportunities

Validating its ModBind™ platform by advancing its lead CatC inhibitor into the clinic could attract significant partnership deals, while its highly selective KIT and novel PARG inhibitors address large markets with unmet needs in allergy and oncology.

Risk Factors

As a preclinical company, it faces high technical risk of clinical failure, dependency on future financing, and competition from larger, well-resourced companies in the same target spaces.

Competitive Landscape

Competes with other computational drug discovery firms (e.g., Relay Therapeutics) and pharma internal efforts; differentiation lies in its specific ModBind™ platform and focus on allosteric inhibition and high selectivity for targets like KIT and PARG.

More companies in Japan →